Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE: Pain Coping Skills and Buprenorphine in Hemodialysis
NCT04571619Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of buprenorphine in chronic pain and opioid use disorder (OUD) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Pain Interference at 12 weeks. Started Jan 2021; status: completed.
02
Drugs
buprenorphine
03
Conditions
chronic painopioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04571619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571619.